23.90
-1.12 (-4.48%)
| Penutupan Terdahulu | 25.02 |
| Buka | 24.53 |
| Jumlah Dagangan | 2,180,802 |
| Purata Dagangan (3B) | 1,194,466 |
| Modal Pasaran | 1,969,347,584 |
| Harga / Buku (P/B) | 3.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| EPS Cair (TTM) | -3.75 |
| Nisbah Semasa (MRQ) | 26.48 |
| Aliran Tunai Operasi (OCF TTM) | -192.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.17 M |
| Pulangan Atas Aset (ROA TTM) | -35.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Mineralys Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.40% |
| % Dimiliki oleh Institusi | 103.83% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Catalys Pacific, Llc | 31 Dec 2025 | 7,903,838 |
| Samsara Biocapital, Llc | 31 Dec 2025 | 5,871,018 |
| Caligan Partners Lp | 31 Dec 2025 | 2,772,654 |
| Holocene Advisors, Lp | 31 Dec 2025 | 1,602,035 |
| Andera Partners | 31 Dec 2025 | 1,591,917 |
| Sr One Capital Management, Lp | 31 Dec 2025 | 1,563,966 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RODMAN DAVID MALCOM | - | 27.24 | -2,171 | -59,138 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,171 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -59,138 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 27.24 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RODMAN DAVID MALCOM | Pegawai | 09 Mar 2026 | Jual automatik (-) | 2,171 | 27.24 | 59,138 |
| RODMAN DAVID MALCOM | Pegawai | 09 Mar 2026 | Pelaksanaan pilihan | 2,171 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2026 | Pengumuman | Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |